DLDavid A. Lomas

David A. Lomas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David A. Lomas has a total of 410 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BMN 349, a small molecule inhibitor of Z alpha-1 antitrypsin polymerization, increases secretion and reduces intrahepatic inclusions in a mouse model of disease

    by Britta Handyside, Heather Wenzel, Donald Mackenzie, Catherine Chang, Annie Greenslade, Jeremy Van Vleet, Brian Heglar, Joseph C. Chen, Lening Zhang, Kevin Larimore, et al.

    Background and Aims: Alpha-1 antitrypsin (AAT), encoded by the SERPINA1 gene, is primarily synthesized in the liver and secreted into the blood. The SERPINA1 Z allele encodes Z-AAT (Glu342Lys), a variant that self-associates into polymers that are retained in hepatocytes and trigger inflammation and hepatic injury. Targeting and preventing Z-AAT polymerization allows a therapy to directly address the pathophysiology of AAT deficiency (AATD) associated liver disease. Approach and Results: A structure-based design approach was used to develop BMN 349, a small-molecule polymerization blocker capable of stabilizing Z-AAT to prevent new polymerization and promote hepatic clearance. BMN 349 bound Z-AAT ~150 times faster in vitro than wild-type M-AAT and promoted secretion and reduced polymer levels in a cell model of Z-AAT deficiency. Crystallography with M-AAT showed that BMN 349 partially displaces a region involved in polymerization, the reactive center loop proximal hinge. Oral dosing in female PiZ transgenic mice with 20–200 mg/kg/day BMN 349 for 30 days was associated with dose-dependent increases in total plasma Z-AAT and a concurrent decrease in circulating and liver Z-AAT polymers relative to vehicle-treated controls. Histopathologic and proteomic assessments of liver and plasma samples from these mice showed that doses ≥100 mg/kg/day of BMN 349 reduced liver inflammation and improved liver health biomarkers after 30 days. Conclusions: This study is the first to demonstrate a reduction in Z-AAT polymer burden without altering protein expression. Improvements in liver inflammation and function following BMN 349 treatment support further investigations of its therapeutic benefits for AATD liver disease.


  • Open Access

    Resolution of the circulating pathogenic phenotype of alpha-1 antitrypsin deficiency following liver transplantation

    by Nina Heyer-Chauhan, Riccardo Ronzoni, Ibrahim Aldobiyan, Elena Miranda, Aileen Marshall, John R. Hurst, James A. Irving, David A. Lomas

    Alpha-1 antitrypsin is a member of the serpin family of protease inhibitors and normally found in monomeric form at high concentration in the circulation. Certain pathogenic variants of this protein self-assemble into flexible chains (polymers) that undergo toxic accumulation in the liver, underlying the development of liver disease, and a corresponding functional deficiency in circulation results in a susceptibility to chronic damage to the lungs and thereby COPD. A proportion of these polymers are detectable in the circulation. This study aimed to provide data on the dynamics of AAT monomers and polymers in the circulation after correction of a deficiency state by liver transplantation. The evolution of the circulating AAT phenotype was characterised quantitatively over time by analysis of blood samples taken pre- and post-liver transplant from three PiZZ AAT deficiency patients, using a panel of conformer-specific monoclonal antibodies and a novel ELISA with enhanced sensitivity for AAT polymers. Circulating wild-type M AAT was found to increase with a half-time of 29-39 h, attaining a clinically-defined putative ‘protective’ threshold level within 24-50 h post-transplant. Baseline circulating polymer levels ranged from 5-35 μg/mL with a half-time clearance of 3-12 h following transplant, and levels were indistinguishable from reference wild-type plasma 22 months post-surgery. The glycosylation profile and disappearance of detectable circulating polymers of AAT were consistent with their origin in, and canonical secretion by, the liver. To our knowledge this is the first post-transplant evaluation of the hybrid conformational profile of endogenous and donor tissue-derived AAT.

  • Open Access

    The mechanism of pathogenic α 1 -antitrypsin aggregation in the human liver

    by Ibrahim Aldobiyan, Emma L. K. Elliston, Narinder Heyer-Chauhan, Stefan T. Arold, Lingyun Zhao, Brandon Huntington, Sarah M. Lowen, Elena V. Orlova, James A. Irving, David A. Lomas

    Originating 2 to 3 millennia ago in a Scandinavian population, the SERPINA1 Z allele (Glu342Lys) is present in up to 2.5% of populations of Northern European descent and accounts for 95% of severe α 1 -antitrypsin deficiency. The α 1 -antitrypsin Z variant self-assembles into polymer chains that deposit within hepatocytes, predisposing to liver disease. Here, the 4.0Å subunit structure of polymers isolated directly from human liver tissue has been determined using cryoelectron microscopy. Challenges of flexibility, small subunit size, heterogeneous length, and preferred orientations were mitigated using antibody Fab domains and sample preparation strategies. This structure demonstrates that the formation of polymers in vivo involves self-incorporation of an exposed structural element (the reactive center loop) as an additional β-strand into the central β-sheet of α 1 -antitrypsin and displacement of a C-terminal region from one subunit with incorporation into the next. Unlike amyloid aggregation, this well-folded structure partially recapitulates a conformation adopted during normal function of the protein. These perturbations to the constituent α 1 -antitrypsin subunits of human tissue-derived polymers are consistent with a pronounced stability, their tendency toward long-chain forms, the ability of a subset to undergo canonical secretion, and the action of a class of small molecules that block polymerization in vivo.


  • Open Access

    Both terminal misfolding and polymerisation contribute to disease-relevant responses in cell models of α 1 -antitrypsin deficiency-associated liver disease

    by Panayiota Stylianou, Kish Adoni, Mun Peak Nyon, Adam Cryar, Imran Haq, Jennifer A. Dickens, Charis-Patricia Segeritz, Graeme C. Smith, Adriana Ordonez, James A. Irving, et al.

    Polymerisation of α 1 -antitrypsin within hepatocytes is considered central to the pathogenesis of α 1 -antitrypsin deficiency-associated liver fibrosis, most commonly in homozygotes for the Z (p.Glu342Lys) allele. Polymerisation proceeds via self-association of monomeric intermediate states. In parallel, >50% of synthesised Z α 1 -antitrypsin is instead recognized as terminally-misfolded and degraded. It is unclear whether this contributes to Z α 1 -antitrypsin deficiency-associated liver disease. We characterised the relationships between polymer formation, terminal misfolding and their cellular consequences, using label-free proteomics mass spectrometry (MS), light and electron microscopy, and cellular assays. Proteomic analyses of well-established CHO cell models of hepatocyte handling of α 1 -antitrypsin variants indicated that cellular responses to the Z mutation were surprisingly similar to those seen with the Null HongKong variant (NHK), which can only misfold terminally and cannot polymerise. A minor set of proteins showed increases associated with Z and not NHK α 1 -antitrypsin expression, consistent with a polymer-specific response, characterized by association with increased organellar organization and vesicle-mediated transport. Conversely, proteostatic and pro-fibrotic integrin-associated pathways increased with the degree of terminal misfolding of the expressed α 1 -antitrypsin variant. Bioenergetic pathway changes indicated concomitant switching from oxidative to glycolytic metabolism. Cell studies further correlated fibrosis-associated behaviours with terminal misfolding rather than polymerisation. Terminal misfolding, as well as polymerisation behaviour, may therefore be important for pro-fibrotic responses including metabolic reprogramming and senescence in Z α 1 -antitrypsin deficiency. Molecular therapies may prove most efficacious for associated liver disease if they address terminal misfolding as well as polymerisation.

  • Open Access

    Susceptibility of alpha-1 antitrypsin deficiency variants to polymer-blocking therapy

    by Riccardo Ronzoni, Ibrahim Aldobiyan, Elena Miranda, Narinder Heyer-Chauhan, Emma L.K. Elliston, Juan Pérez, Annamaria Fra, James A. Irving, David A. Lomas

    The Z variant (Glu342Lys) causes alpha-1 antitrypsin (AAT) to self-assemble into polymer chains that accumulate within hepatocytes, causing liver disease and exposing a cryptic epitope recognized by the 2C1 monoclonal antibody (mAb). They can be blocked by the small molecule GSK716 (‘716) that stabilizes an intermediate on the polymerization pathway. We have characterized 23 mutants of AAT in a cellular model to establish: (a) their ability to form intracellular polymers, (b) whether polymer formation could be prevented by ‘716, and (c) whether the polymers expose the 2C1 cryptic epitope. Most of the variants, including Mprocida (Leu41Pro), Mherleen (Pro369Leu), Mduarte (Asp256Val), Lfrankfurt (Pro255Thr), Yorzinuovi (Pro391His), Mwurzburg (Pro369Ser), and p.289S accumulated as intracellular polymers. Eleven formed polymers that were resistant to ‘716, including Mprocida, Mmalton (ΔPhe51), Lfrankfurt, Mduarte, S (Glu264Val), Mherleen, and Yorzinuovi. The ‘716 resistant mutants localize to a region of the AAT molecule separate from the binding site of the small molecule and form polymers that are less well recognized by the 2C1 mAb. They are fully recognized by a novel 8A7 mAb that we developed to have a broader specificity. Our data suggest that individuals with these mutations are unlikely to benefit from treatment with ‘716 or its derivatives.


  • Open Access

    High-resolution characterization of ex vivo AAT polymers by solution-state NMR spectroscopy

    by Sarah M. Lowen, Christopher A. Waudby, Alistair M. Jagger, Ibrahim Aldobiyan, Mattia Laffranchi, Annamaria Fra, John Christodoulou, James A. Irving, David A. Lomas

    Serpins, protease inhibitors whose regulated conformational instability renders them susceptible to mutations that cause misfolding, represent a system for the study of non-amyloid protein aggregation. The E342K “Z” variant of α-1-antitrypsin (AAT) undergoes oligomeric self-assembly into polymer chains that are associated with liver and lung pathologies in AAT deficiency. Structural characterization of polymers from human tissue has been limited by their heterogeneity and flexibility; here, we have studied their internal structure, which provides insights into the molecular linkage and the pathway by which they are formed. NMR spectra of heat-induced 13 C-ILV-methyl–labeled polymers, and 1 H-methyl spectra of liver-derived polymers, show equivalence to that of AAT in a post–protease-encounter conformation. This is corroborated by x-ray crystallography, which reveals a cryptic epitope recognized by the conformationally selective 2C1 antibody, common to both forms. These data definitively preclude most models of polymerization and are compatible with sequential intermolecular donation of the carboxyl terminus of one molecule into the next during polymer formation.


  • Open Access

    Visualisation of translating ribosomes reveals the earliest steps of protein misfolding in human disease

    by Elena Plessa, Lien P. Chu, Charity R. Hornby, Julian O. Streit, Alkistis N. Mitropoulou, Sammy H.S. Chan, James A. Irving, David A. Lomas, John Christodoulou, Lisa D. Cabrita

    The majority of cellular proteins must adopt a particular three-dimensional structure for function 1 . However, protein folding is a perilous journey due to competing polypeptide misfolding events which result in inactive structures. In this study, we examine the earliest steps of protein misfolding during the biosynthesis of alpha-1-antitrypsin, a secreted plasma protein whose misfolding results in organ disease. Using human cells, we find that, like co-translational protein folding, misfolding, assembly and biosynthesis are interconnected processes. At the molecular level misfolding of alpha-1-antitrypsin is initiated by a molten globule-like folding intermediate formed cotranslationally on the ribosome. The ribosomal complexes subsequently form assemblies by recruiting released proteins, inducing translational arrest. Our data also reveal that a pharmacological chaperone modulates this process. The existence of co- and post-translational (mis)folding and assembly pathways reveals how some proteins form functional complexes, has implications for the pathogenesis of conformational diseases, and suggests novel therapeutic avenues.


  • Open Access

    Top-Down Ion Mobility Mass Spectrometry Reveals a Disease Associated Conformational Ensemble of Alpha-1-antitrypsin

    by Sarah Vickers, Ibrahim Aldobiyan, Sarah M. Lowen, James A. Irving, David A. Lomas, Konstantinos Thalassinos

    Mutants of members of the serpin superfamily can undergo nonamyloid aggregation to form polymeric chains that are associated with disease. This is typified by Z alpha-1-antitrypsin (Glu342Lys) that accumulates as polymers within hepatocytes to cause cirrhosis. We have used ion mobility mass spectrometry and electron-capture dissociation to directly observe and characterize novel intermediates formed during polymerization. Our data are congruent with an ensemble of conformations that are monomeric but maintained in a partially misfolded metastable state in which ∼12% of the molecule at the C-terminus is displaced. The application of these techniques to Z alpha-1-antitrypsin polymers isolated from human liver revealed a molecular species most consistent with a polymer mediated by an intermolecular C-terminal domain insertion. These findings establish a previously unobserved progression of pathogenic structural changes and thereby extend the mechanism of alpha-1-antitrypsin polymerization. They additionally demonstrate the strengths of native top-down ion mobility mass spectrometry in characterizing misfolding intermediates and proteins isolated from human tissue.


  • Open Access

    Assessing Inflammatory Protein Biomarkers in COPD Subjects with and without Alpha-1 Antitrypsin Deficiency

    by Matthew Moll, Brian D. Hobbs, Katherine A. Pratte, Chengyue Zhang, Auyon J. Ghosh, Russell P. Bowler, David A Lomas, Edwin K. Silverman, Dawn L. DeMeo

    Rationale: Individuals homozygous for the Alpha-1 Antitrypsin (AAT) Z allele (Pi*ZZ) exhibit heterogeneity in COPD risk. COPD occurrence in non-smokers with AAT deficiency (AATD) suggests inflammatory processes may contribute to COPD risk independently of smoking. We hypothesized that inflammatory protein biomarkers in non-AATD COPD are associated with moderate-to-severe COPD in AATD individuals, after accounting for clinical factors. Methods: Participants from the COPDGene (Pi*MM) and AAT Genetic Modifier Study (Pi*ZZ) were included. Proteins associated with FEV 1 /FVC were identified, adjusting for confounders and familial relatedness. Lung-specific protein-protein interaction (PPI) networks were constructed. Proteins associated with AAT augmentation therapy were identified, and drug repurposing analyses performed. A protein risk score (protRS) was developed in COPDGene and validated in AAT GMS using AUC analysis. Machine learning ranked proteomic predictors, adjusting for age, sex, and smoking history. Results: Among 4,446 Pi*MM and 352 Pi*ZZ individuals, sixteen blood proteins were associated with airflow obstruction, fourteen of which were highly expressed in lung. PPI networks implicated regulation of immune system function, cytokine and interleukin signaling, and matrix metalloproteinases. Eleven proteins, including IL4R, were linked to augmentation therapy. Drug repurposing identified antibiotics, thyroid medications, hormone therapies, and antihistamines as potential AATD treatments. Adding protRS improved COPD prediction in AAT GMS (AUC 0.86 vs. 0.80, p = 0.0001). AGER was the top-ranked protein predictor of COPD. Conclusions: Sixteen proteins are associated with COPD and inflammatory processes that predict airflow obstruction in AATD after accounting for age and smoking. Immune activation and inflammation are modulators of COPD risk in AATD.